Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Name: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Published: 2017
License: Public Domain

AstraZeneca · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

nsclc progression

non small cell lung cancer nsclc, nsclc, programmed cell death ligand 1 (pd-l1), durvalumab, tremelimumab, progression-free survival (pfs), overall survival (os), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Related documents